Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

TSU-68 active in phase I/II hepatocellular carcinoma trial

June 20, 2008

Phase II data reported for ixabepilone in renal cell carcinoma, prostate cancer, pediatric tumors

June 20, 2008

Phase I results reported for oncolytic compounds from Bristol-Myers Squibb

June 19, 2008

Data on GSK-1363089 in papillary renal carcinoma, gastric cancer presented

June 19, 2008

Responses seen with PF-00299804 in patients with advanced non-small cell lung cancer

June 19, 2008

Spectrum selects Fusilev as tradename for levoleucovorin for injection

June 18, 2008

Adventrx reports CoFactor phase IIb overall survival results

June 18, 2008

Oncothyreon initiates phase I PX-866 trial in patients with solid tumors

June 18, 2008

JX-594 well tolerated, active in refractory primary and metastatic liver cancer

June 18, 2008

Exelixis and FDA agree on Special Protocol Assessment for XL-184 phase III trial

June 18, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 16, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...